COVID-19 Publications - Week 05 2021 1328 Publications

Total Page:16

File Type:pdf, Size:1020Kb

COVID-19 Publications - Week 05 2021 1328 Publications Update February 1 - February 7, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 05 2021 1328 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers, Disinfectant Devices, and Air Purifiers (FDA, 2020) Breast Cancer Patient Triage Guidelines (CPBCC, 2020) clinical guidance for adult Belgian patients with suspected or confirmed COVID-19 National Covid-19 Testing Action Plan (Rockefeller Foundation) ASE issues Echo-cardiography guidance Trials & Registries CAPACITY European registry COVID 19 patients WHO launches global megatrial FDA launches Convalescent plasma trial Lets Beat Covid-19 Survey to help plan hospital services COVID IBD registry Google mobility reports per country COVID 19 World's largest trial of potential coronavirus treatments rolled out across the UK Pregnancy Registry (US) ICNARC report on COVID-19 in critical care - NHS April 24 COVID-19 Human Genetics - Biobanks COVID19 settings of transmission database COVID-19 prevention network Covid-Plex trial - (plasma exchange & convalescent plasma trial) The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma. If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark Covid-Plex trial Mainstream Media New York Times - Corona update How Merck, a Vaccine Titan, Lost the Covid Race WHO Panel Recommends AstraZeneca Vaccine Despite Variant Concerns U.K. residents may not be allowed to travel abroad until all adults are vaccinated. Half of U.S. Coronavirus Deaths Have Come Since Nov. 1 Could a Single Vaccine Work Against All Coronaviruses? People With Dementia Are Twice as Likely to Get Covid, Huge Study Finds Coronavirus Variants and Mutations A Few Covid Vaccine Recipients Developed a Rare Blood Disorder Coronavirus Vaccine Tracker Coronavirus Drug and Treatment Tracker Washington Post - Corona update France is seeing a baby bust nine months after its first covid lockdown No quarantine needed who have received both shots of coronavirus vaccine, Masks should fit better or be doubled up to protect against coronavirus variants, U.K. coronavirus restrictions to include hotel quarantines, threats of fines and prison Denmark says it has U.K. coronavirus variant under control, for now CDC weighs coronavirus testing requirement for flights, industry voices opposition Variants mean the coronavirus is here to stay — but perhaps as a lesser threat What we know about how the coronavirus started, and why it matters ‘Coronaphobia’: Covid anxiety has a name. Here’s how to cope. Guardian - Corona update ‘It’s impossible to pay’: the UK residents trapped overseas by quarantine rules Coronavirus live: international travel 'biggest factor in death rate' US could have averted 40% of Covid deaths, says panel examining Trump's policies Before you compare the Covid vaccines, here are five things to know Vaccination passports are nothing new – and the sooner we have them Key Articles 1. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. J. Clin. Apher. 2021; Vegivinti CTR, Pederson JM, Saravu K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33544910 The potential benefit of convalescent plasma therapy in COVID-19 seems self- evident based on a long experience of using this approach in other infectious diseases. This meta-analysis screened 859 (!) studies and identified 15 articles that fit the inclusion criteria. Overall total mortality was significantly reduced, OR: 0.59 (0.44-0.78; P<0.001), but two key RCTs failed to support this. Clinical improvement was favorable in patients treated with convalescent plasma, OR:2.02 (1.54-2.65; P<0.001). No differences in duration of hospital stay were observed, MD=-0.49 (-3.11 to 2.12; P=0.713) 2. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out- of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. Eur Heart J 2021; Sultanian P, Lundgren P, Strömsöe A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33543259 Patients with COVID-19 infections are at increased risk for (fatal) cardiovascular complications partly because of the pathophysiological driving forces of the SARS-CoV2 viral infection and partly because of avoidance to seek proper medical care. Data from the National Swedish Registry for Cardiopulmonary Resuscitation was used to analyse the impact of COVID-19 on in- and out-of- hospital cardiac arrests. COVID-19 was involved in ≥10% of OHCAs and 16% of IHCAs. The 30-day mortality increased 3.4-fold in OHCA and 2.3-fold in IHCA. 3. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung 2021; 50:357-360Salabei JK, Fishman TJ, Asnake ZT et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33524866 Coagulopathies are frequently observed COVID-19 (fatal) complications. This review shares recent insights into the potential etiologies, from direct cytotoxicity, activation of pro-inflammatory molecules, e.g., cytokines, to endothelial cell dysfunction. The authors point out that the observed clinical and laboratory characteristics are distinctly different from sepsis and ARDS associated coagulopathy. Institution specific guidelines for prophylactic anticoagulation are recommended to address the specific needs of the different patient populations cared for. 4. COVID-19-Associated Cytokine Storm Syndrome and Diagnostic Principles: An Old and New Issue. Emerg Microbes Infect 2021:1-30Xi Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=33522893 5. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung 2021; 50:329-333Turgay Yıldırım Ö, Kaya Ş. http://www.ncbi.nlm.nih.gov/pubmed/?term=33524862 6. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth 2021; 21:108Servante J, Swallow G, Thornton JG et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33546624 7. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Transl Med Commun 2021; 6:3Peymani P, Dehesh T, Aligolighasemabadi F et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33521322 8. Prevalence of SARS-CoV-2 in children from a cohort of 2192 patients. Monatsschr. Kinderheilkd. 2021; 169:46-51Meyer M, Rübsteck E, Lehmann C et al. 9. High-dose vitamin D versus placebo to prevent complications in COVID- 19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL). Trials 2021; 22:111Mariani J, Tajer C, Antonietti L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33522946 10. The Incidence, Prognosis and Laboratory Indicators of Venous Thromboembolism in Hospitalized Patients with COVID-19: A Systematic Review and Meta-analysis. J Vasc Surg Venous Lymphat Disord 2021; Liu Y, Cai J, Wang C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33529719 11. Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention. Front Cardiovasc Med 2020; 7:599334Liu H, Wang Z, Sun H et al. http://www.ncbi.nlm.nih.gov/pubmed/? term=33537347 12. Beneficial Effect of Statins in COVID-19-Related Outcomes: A National Population-Based Cohort Study. Arterioscler. Thromb. Vasc. Biol. 2021:Atvbaha120315551Lee HY, Ahn J, Park J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33535790 13. Cardiac arrest and COVID-19: inflammation, angiotensin-converting enzyme 2, and the destabilization of non-significant coronary artery disease-a case report. Eur Heart J Case Rep 2021; 5:ytaa475Colombier S, Mahendiran T, Niclauss L, Kirsch M. http://www.ncbi.nlm.nih.gov/pubmed/? term=33542974 14. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity. Antioxidants (Basel) 2021; 10Cho KH, Kim JR, Lee IC, Kwon HJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=33535459 15. Steroid harms if given early in COVID-19 viraemia. BMJ Case Rep. 2021; 14Arora K, Panda PK. http://www.ncbi.nlm.nih.gov/pubmed/?term=33541971 Basic Science (68 articles) 1. Regeneration Profiles of Olfactory Epithelium after SARS-CoV-2 Infection in Golden Syrian Hamsters. ACS Chem Neurosci 2021; Urata S, Maruyama J, Kishimoto-Urata M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=33522795 2.
Recommended publications
  • Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
    pharmaceutics Article Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes Franklin Afinjuomo 1, Thomas G. Barclay 1, Ankit Parikh 1, Yunmei Song 1, Rosa Chung 1, Lixin Wang 1, Liang Liu 1, John D. Hayball 1, Nikolai Petrovsky 2,3 and Sanjay Garg 1,* 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia; olumide.afi[email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (Y.S.); [email protected] (R.C.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 2 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; nikolai.petrovsky@flinders.edu.au 3 Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia * Correspondence: [email protected]; Tel.: +61-8-8302-1567 Received: 26 April 2019; Accepted: 16 May 2019; Published: 22 May 2019 Abstract: The propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less effective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker.
    [Show full text]
  • Advances in Nanomaterials in Biomedicine
    nanomaterials Editorial Advances in Nanomaterials in Biomedicine Elena Ryabchikova Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, 8 Lavrentiev Ave., 630090 Novosibirsk, Russia; [email protected] Keywords: nanotechnology; nanomedicine; biocompatible nanomaterials; diagnostics; nanocarriers; targeted drug delivery; tissue engineering Biomedicine is actively developing a methodological network that brings together biological research and its medical applications. Biomedicine, in fact, is at the front flank of the creation of the latest technologies for various fields in medicine, and, obviously, nanotechnologies occupy an important place at this flank. Based on the well-known breadth of the concept of “Biomedicine”, the boundaries of the Special Issue “Advances in Nanomaterials in Biomedicine” were not limited, and authors could present their work from various fields of nanotechnology, as well as new methods and nanomaterials intended for medical applications. This approach made it possible to make public not only specific developments, but also served as a kind of mirror reflecting the most active interest of researchers in a particular field of application of nanotechnology in biomedicine. The Special Issue brought together more than 110 authors from different countries, who submitted 11 original research articles and 7 reviews, and conveyed their vision of the problems of nanomaterials in biomedicine to the readers. A detailed and well-illustrated review on the main problems of nanomedicine in onco-immunotherapy was presented by Acebes-Fernández and co-authors [1]. It should be noted that the review is not limited to onco-immunotherapy, and gives a complete understanding of nanomedicine in general, which is useful for those new to this field.
    [Show full text]
  • Introducing Bionanotechnology Into Undergraduate Biomedical Engineering
    AC 2009-504: INTRODUCING BIONANOTECHNOLOGY INTO UNDERGRADUATE BIOMEDICAL ENGINEERING Aura Gimm, Duke University J. Aura Gimm is Assistant Professor of the Practice and Associated Director of Undergraduate Studies in the Department of Biomedical Engineering at Duke University. She teaches courses in biomaterials, thermodynamics/kinetics, engineering design, and a new course in bionanotechnology. Dr. Gimm received her S.B. in Chemical Engineering and Biology from MIT, and her Ph.D. in Bioengineering from UC-Berkeley. Page 14.802.1 Page © American Society for Engineering Education, 2009 Introducing Bionanotechnology in Undergraduate Biomedical Engineering Abstract As a part of the NSF-funded Nanotechnology Undergraduate Education Program, we have developed and implemented a new upper division elective course in Biomedical Engineering titled “Introduction to Bionanotechnology Engineering”. The pilot course included five hands- on “Nanolab” modules that guided students through specific aspects of nanomaterials and engineering design in addition to lecture topics such as scaling effects, quantum effects, electrical/optical properties at nanoscale, self-assembly, nanostructures, nanofabrication, biomotors, biological designing, biosensors, etc. Students also interacted with researchers currently working in the areas of nanomedicine, self-assembly, tribiology, and nanobiomaterials to learn first-hand the engineering and design challenges. The course culminated with research or design proposals and oral presentations that addressed specific engineering/design issues facing nanobiotechnology and/or nanomedicine. The assessment also included an exam (only first offering), laboratory write-ups, reading of research journal articles and analysis, and an essay on ethical/societal implications of nanotechnology, and summative questionnaire. The course exposed students to cross-disciplinary intersections that occur between biomedical engineering, materials science, chemistry, physics, and biology when working at the nanoscale.
    [Show full text]
  • Nanotechnology in Regenerative Medicine: the Materials Side
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UPCommons. Portal del coneixement obert de la UPC Review Nanotechnology in regenerative medicine: the materials side Elisabeth Engel, Alexandra Michiardi, Melba Navarro, Damien Lacroix and Josep A. Planell Institute for Bioengineering of Catalonia (IBEC), Department of Materials Science, Technical University of Catalonia, CIBER BBN, Barcelona, Spain Regenerative medicine is an emerging multidisciplinary structures and materials with nanoscale features that can field that aims to restore, maintain or enhance tissues mimic the natural environment of cells, to promote certain and hence organ functions. Regeneration of tissues can functions, such as cell adhesion, cell mobility and cell be achieved by the combination of living cells, which will differentiation. provide biological functionality, and materials, which act Nanomaterials used in biomedical applications include as scaffolds to support cell proliferation. Mammalian nanoparticles for molecules delivery (drugs, growth fac- cells behave in vivo in response to the biological signals tors, DNA), nanofibres for tissue scaffolds, surface modifi- they receive from the surrounding environment, which is cations of implantable materials or nanodevices, such as structured by nanometre-scaled components. Therefore, biosensors. The combination of these elements within materials used in repairing the human body have to tissue engineering (TE) is an excellent example of the reproduce the correct signals that guide the cells great potential of nanotechnology applied to regenerative towards a desirable behaviour. Nanotechnology is not medicine. The ideal goal of regenerative medicine is the in only an excellent tool to produce material structures that vivo regeneration or, alternatively, the in vitro generation mimic the biological ones but also holds the promise of of a complex functional organ consisting of a scaffold made providing efficient delivery systems.
    [Show full text]
  • Cancer Nanomedicine: from Targeted Delivery to Combination Therapy
    Review Cancer nanomedicine: from targeted delivery to combination therapy 1,2,3 1 1 1,2 Xiaoyang Xu , William Ho , Xueqing Zhang , Nicolas Bertrand , and 1 Omid Farokhzad 1 Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 2 The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3 Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA The advent of nanomedicine marks an unparalleled op- advantages of NPs have brought widespread attention to portunity to advance the treatment of various diseases, the field of nanomedicine, including their large ratio of including cancer. The unique properties of nanoparticles volume to surface area, modifiable external shell, biode- (NPs), such as large surface-to-volume ratio, small size, gradability, and low cytotoxicity [4]. Furthermore, nano- the ability to encapsulate various drugs, and tunable medicine brings us dramatically closer to realizing the full surface chemistry, give them many advantages over their promise of personalized medicine [5]. bulk counterparts. This includes multivalent surface mod- Engineered therapeutic NPs offer numerous clinical ification with targeting ligands, efficient navigation of the advantages. Surface modification with polyethylene glycol complex in vivo environment, increased intracellular traf- (PEG) protects NPs from clearance from the blood by the ficking, and sustained release of drug payload. These mononuclear phagocytic system (MPS), markedly increasing advantages make NPs a mode of treatment potentially both circulation times and drug uptake by target cells superior to conventional cancer therapies. This review [2,6].
    [Show full text]
  • COVID-19 Publications - Week 22 2020 709 Publications
    Update May 25 - May 31, 2020, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 22 2020 709 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers,
    [Show full text]
  • Personalized Nanomedicine
    Published OnlineFirst July 24, 2012; DOI: 10.1158/1078-0432.CCR-12-1414 Clinical Cancer Perspective Research Personalized Nanomedicine Twan Lammers1,2,3, Larissa Y. Rizzo1, Gert Storm2,3, and Fabian Kiessling1 Abstract Personalized medicine aims to individualize chemotherapeutic interventions on the basis of ex vivo and in vivo information on patient- and disease-specific characteristics. By noninvasively visualizing how well image-guided nanomedicines—that is, submicrometer-sized drug delivery systems containing both drugs and imaging agents within a single formulation, and designed to more specifically deliver drug molecules to pathologic sites—accumulate at the target site, patients likely to respond to nanomedicine-based therapeutic interventions may be preselected. In addition, by longitudinally monitoring how well patients respond to nanomedicine-based therapeutic interventions, drug doses and treatment protocols can be individualized and optimized during follow-up. Furthermore, noninvasive imaging information on the accumulation of nanomedicine formulations in potentially endangered healthy tissues may be used to exclude patients from further treatment. Consequently, combining noninvasive imaging with tumor-targeted drug delivery seems to hold significant potential for personalizing nanomedicine-based chemotherapeutic interventions, to achieve delivery of the right drug to the right location in the right patient at the right time. Clin Cancer Res; 18(18); 4889–94. Ó2012 AACR. Introduction Similarly, immunohistochemical tests evaluating the pro- Personalized medicine is often heralded as one of the tein expression levels of HER2, epidermal growth factor major leaps forward for 21st century medical practice (1). It receptor (EGFR), and c-kit in metastatic breast, colorectal, aims to individualize therapeutic interventions, incorpo- and gastrointestinal tumors, respectively, are approved by rating not only information obtained using ex vivo genetic the U.S.
    [Show full text]
  • Nanotechnology Enabled Regenerative Medicine for Neurological Disorders
    Advanced Drug Delivery Reviews 148 (2019) 1–2 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Nanotechnology enabled regenerative medicine for neurological disorders Tao L. Lowe a,⁎, Vivek Agrahari b, Rangaramanujam M. Kannan c, Sujatha Kannan d Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA CONRAD, Eastern Virginia Medical School, Arlington, VA 22209, USA Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Regenerative therapy has evolved significantly in recent years with endogenous regenerative pathways in the brain. The authors discuss promising approaches to restore function of diseased, damaged and nanotechnology-based approaches that target cellular and extracellular aged tissues and organs. It is a highly interdisciplinary field that has components to enhance neural regeneration while suppressing cellular been made possible by the intersection of recent advances in bioengi- and extracellular inhibitory mechanisms triggered by injury that could neering, stem cell biology and nanotechnology. Incorporation of nano- impair repair and plasticity in the brain. In the perspective review by technology may allow better control over physicochemical and the Ferriero group [2], the unique challenges in considering advanced biological properties of a biomaterial compared to conventional tech- regenerative therapies in the newborn brain are discussed. Newborn nologies. Nanotechnology applications to regenerative therapy have brains are immature and actively changing due to normal brain devel- all the potential to revolutionize tissue regeneration and repair, and ul- opment.
    [Show full text]
  • The Emerging Therapy of Tomorrow with Nanomedicine: Present Status R Kumar
    The Internet Journal of Neurology ISPUB.COM Volume 10 Number 1 The Emerging Therapy of Tomorrow with Nanomedicine: Present Status R Kumar Citation R Kumar. The Emerging Therapy of Tomorrow with Nanomedicine: Present Status. The Internet Journal of Neurology. 2007 Volume 10 Number 1. Abstract Nanomedicine is new concept in combining nanotechnology and medicine. Nanotherapeutics is the use of nanomedicine in therapy. The definition of nanomedicine require attention as the nanotechnology represents a cluster of technologies. This article outlines present development in nanomedicine and prospect in nanotherapeutics. Health and safety issues also are discussed. Richard Feynman a nobel Laurete predicted the emergence nanoscale technologies to the practice of medicine. It is used of a new science called nanotechnology in 1959, as this for diagnosis, prevention and treatment of disease and to deals with structure of one to one hundred nanometers in gain increased understanding of underlying disease scale 1 . Nanotechnology is term used to define the products, mechanisms. Presently nanomedicine involves detection of processes and properties at the nano/micro scale that have particles, drug delivery system, emulsions, and carriers for resulted from the convergence of the physical, chemical and delivering vaccines: and biomaterials with unusual life sciences. National Nanotechnology Initiative (NNI) properties and improved biocompatibility. Nanotechnology defines nanotechnology as research and development at the is also biomimicry i.e. to understand the natures solution atomic, molecular or macromolecular levels in the towards biological system or to learn from nature 6 . sub-100nm range (0.1-100nm) create structure, devices, and Potential of nanomedicine market: “The market of system that have novel functional properties 2,3 .
    [Show full text]
  • How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases
    pharmaceuticals Review Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases Abdelfattah Faouzi 1 and Valérie Gaëlle Roullin 2,* 1 Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO 63131, USA; [email protected] 2 Laboratoire de Nanotechnologies Pharmaceutiques, Faculté de Pharmacie, Université de Montréal, Montréal, QC H3T 1J4, Canada * Correspondence: [email protected]; Tel.: +1-514-343-6111 (ext. 0687) Abstract: The complexity and organization of the central nervous system (CNS) is widely modu- lated by the presence of the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB), which both act as biochemical, dynamic obstacles impeding any type of undesirable ex- ogenous exchanges. The disruption of these barriers is usually associated with the development of neuropathologies which can be the consequence of genetic disorders, local antigenic invasions, or autoimmune diseases. These disorders can take the shape of rare CNS-related diseases (other than Alzheimer’s and Parkinson’s) which a exhibit relatively low or moderate prevalence and could be part of a potential line of treatments from current nanotargeted therapies. Indeed, one of the most promising therapeutical alternatives in that field comes from the development of nanotechnologies which can be divided between drug delivery systems and diagnostic tools. Unfortunately, the num- ber of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly due to a lack of interest from industrial pharmaceutical companies. In the present review, we will provide an overview of some of these rare CNS diseases, discuss the physiopathology of these disorders, shed light on how nanotherapies could be of interest as a credible line of treatment, and Citation: Faouzi, A.; Roullin, V.G.
    [Show full text]
  • Applications of Nanomedicine by Sanjeeb K Sahoo, Ph.D
    www.asiabiotech.com Special Feature - Nanobiotechnology/Nanomedicine Applications of Nanomedicine by Sanjeeb K Sahoo, Ph.D Introduction ne of the most promising applications of nanotechnology is in the fi eld of medicine. Indeed, a whole new fi eld of “nanomedicine” is emerging. Nanomedicine has been defi ned as the monitoring, repair, Oconstruction and control of human biological systems at the molecular level using engineered nanodevices and nanostructures.1 It can also be regarded as another implementation of nanotechnology in the fi eld of medical science and diagnostics. The National Cancer Institute and the National Aeronautics & Space Administration, USA are working to develop nano-sized technologies that can detect, diagnose, and treat disease. Researchers in this fi eld are “confi dent that they are going to turn healthcare inside out.” Richard Smalley, a Nobel Prize-winning chemist at Rice University, USA, described to the Congress how the potential of nanotechnology can transform medicine: Twenty years from now, nanotechnology will have given us specially engineered drugs that specifi cally target just the mutant cancer cells in the human body, and leave everything else blissfully alone. Cancer will be a thing of the past.2 Nanotechnology can be defi ned as the science and engineering involved in the design, synthesis, characterization, and application of materials and devices whose smallest functional organization in at least one dimension is on the nanometer scale or one billionth of a meter. The prefi x “nano” is derived from the Greek word for dwarf. One nanometer (nm) is equal to one-billionth of a meter, or about the width of six carbon atoms or ten water molecules.
    [Show full text]
  • Nanomedicine to Counter Syndemic Tuberculosis and HIV Infection: Current Knowledge and State of Art
    Nanoscience and Nanoengineering 2(1): 1-9, 2014 http://www.hrpub.org DOI: 10.13189/nn.2014.020101 Nanomedicine to Counter Syndemic Tuberculosis and HIV Infection: Current Knowledge and State of Art Dipankar Seth*, Amit Sarkar, Debalina Mitra Animal Resources Development Department, Government of West Bengal, India *Corresponding Author: [email protected] Copyright © 2014 Horizon Research Publishing All rights reserved Abstract This review examines, current knowledge, of space it’s multi-factorial complexities and potency as an the impact of the HIV-TB disease syndemic with an eye on opportunistic pathogen the burden of tuberculosis toll is still its zoonotic impact and discusses the current knowledge and heavy on the globe even after 100 years of its discovery. the potential of nanomedicine to improve intracellular Besides with the advent of HIV, tuberculosis establishes a disease therapy by offering properties such as targeting, symbiotic relationship to evolve as a deadliest burden to the sustained drug release, and drug delivery to the pathogen’s human world. Syndemic relation of tuberculosis with other intracellular location. Besides the aim of this review is also diseases like diabetes, chronic lung diseases also added to the to identify the gap between available medications and the problem but its concurrent relationship with HIV made the need of the hour, drugs, to counter multi-drug resistance problem even worse. A syndemic is defined as the (mdr) and extensively drug-resistant (XDR) tuberculosis. convergence of two or more diseases that act synergistically This review is the first of its kind to take into consideration to magnify the burden of disease.
    [Show full text]